Dr Leszek Kotula, co-author of the WAVE1 study, explains in this video from 2013  how basic science research in his lab at Upstate Medical University in Syracuse, NY will benefit prostate cancer patients with better diagnostic and treatment options.

April 7, 2015. Researchers at Upstate Medical University, NY and Harvard University have linked the loss of key gene, WAVE1, to a lethal form of prostate cancer. They found that  in patients who were treated for prostate cancer, alterations in the WAVE1 gene were associated with a shorter remission.

...continue reading "Loss of WAVE1 gene linked to lethal prostate cancer"

April 23, 2015. African American men have the highest rates of prostate cancer incidence and mortality in the United States. For the past twenty years cancer researchers have worried about this and researched various causal factors. Now a large study suggests obesity may play an important role in what specialists in disparities in prostate cancer risk are calling the "African-American race effect.

...continue reading "Obesity Significantly Increases Prostate Cancer Risk in African-American Men"

A device to lower side effects of radiation treatment for prostate cancer, newly approved in the USA, has been used this month on the first patient. The device injects a temporary gel to create a space between the prostate and the rectum.

Named the SpaceOAR System (“OAR” stands for “organ at risk”), the system received FDA clearance on April 1. FDA granted clearance after a US clinical trial showing that SpaceOAR hydrogel achieved a significant reduction in rectal radiation dose and late rectal toxicity.
...continue reading "Injectable Gel Improves Radiation for Prostate Cancer"

The PSA test is the first step in the early detection of prostate cancer.

As such it must be used as part of a skilled diagnostic process and selective treatment process. When to start and stop screening, at what intervals to conduct screening, and when to biopsy are among questions we look at here.

...continue reading "PSA Test – do you need it?"

Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for some patients with early-stage prostate cancer.

Peter Carroll and a team at UCSF report the experience of a group of men men with prostate cancer who were managed with active surveillance.

...continue reading "Active Surveillance for Low-Risk Prostate Cancer Demands Careful Selection"